Goodwin Procter advised STALICLA on the deal.STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental disorders…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now